WIKIMEDIA, ANONAllergan, the Dublin-headquartered pharmaceutical company, is maintaining its mergers and acquisitions activity with a $1.7 billion offer to buy San Francisco–based Tobira Therapeutics, according to a joint statement the firms released yesterday (September 20). Allergan has its sights set on Tobira’s experimental therapies for non-alcoholic steatohepatitis (NASH), a common comorbidity of type 2 diabetes characterized by inflammation, fat accumulation, and cellular damage in the liver.
“The acquisition of Tobira is a strategic R&D investment within a white space area of our global Gastroenterology franchise and an opportunity to advance the development of novel treatments for NASH,” Allergan CEO Brent Saunders said in the statement. “With the increasing rates of diabetes, obesity and other metabolic conditions in the U.S. and in developed nations globally, NASH is set to become one of the next epidemic-level chronic diseases we face as a society. It is important that we invest in new treatments today so that healthcare systems, providers and patients have treatment options to face this challenge in the coming years.”
Allergan has made news in recent days with its acquisition of Akarna Therapeutics, which also makes drugs to treat NASH, and its ...
